Stoffwechselerkrankungen der
Leber

M G Donner; A Erhardt; D Häussinger

doi:10.1055/s-0030-1269424

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2010; 135(50): 2540-2547
DOI: 10.1055/s-0030-1269424

Übersicht | Review article

Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

Stoffwechselerkrankungen der Leber

Teil 2: Glykogenosen, hereditäre Fruktoseintoleranz, Galaktosämie und hepatische PorphyrienMetabolic disorders of the liverPart 2: glykogen storage diseases, hereditary fructose intolerance, galactosemia and hepatic porphyrias M. G. Donner¹ , A. Erhardt¹ , D. Häussinger¹

¹Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universität Düsseldorf

Abstract

Schlüsselwörter

Glykogenose - Porphyrie - hereditäre Fruktoseintoleranz - Galaktosämie

Keywords

glycogenosis - porphyria - hereditary fructose intolerance - galactosemia

Full Text

References

Literatur

1 Acosta P B, Gross K C. Hidden sources of galactose in the environment. Eur J Pediatr. 1995; 154 (Suppl 2) 87-92
2 Alaupovic P, Fernandes J. The serum apolipoprotein profile of patients with glucose-6-phosphatase deficiency. Pediatr Res. 1985; 19 380-384
3 Andant C, Puy H, Bogard C, Faivre J et al . Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol. 2000; 32 933-939
4 Anderson K E, Spitz I M, Bardin C W, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med. 1990; 150 1469-1474
5 Anderson K E, Bloomer J R, Bonkovsky H L et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005; 142 439-450
6 Bandsma R H, Prinsen B H, van Der Velden M S et al. Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res. 2008; 63 702-707
7 Beaudet A L, Anderson D C, Michels V V et al. Neutropenia and impaired neutrophil migration in type 1B glycogen storage disease. J Pediatr. 1980; 97 906-910
8 Berry G T, Nissim I, Lin Z, Mazur A T, Gibson J B, Segal S. Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet. 1995; 346 1073-1074
9 Bosch A M. Classical galactosaemia revisited. J Inherit Metab Dis. 2006; 29 516-525
10 Bruno C, van Diggelen O P, Cassandrini D et al. Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV). Neurology. 2004; 63 1053-1058
11 Burwinkel B, Rootwelt T, Kvittingen E A, Chakraborty P K, Kilimann M W. Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the PHKG2 gene. Pediatr Res. 2003; 54 834-839
12 Cohen J L, Vinik A, Faller J, Fox I H. Hyperuricemia in glycogen storage disease type I. Contributions by hypoglycemia and hyperglucagonemia to increased urate production. J Clin Invest. 1985; 75 251-257
13 Cox T M. Aldolase B and fructose intolerance. FASEB J. 1994; 8 62-71
14 Cox T M. The genetic consequences of our sweet tooth. Nat Rev Genet. 2002; 6 481-487
15 Demo E, Frush D, Gottfried M, Koepke J et al . Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?. J Hepatol. 2007; 46 492-498
16 DiMauro S, Hartwig G B, Hays A et al. Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol. 1979; 5 422-436
17 Egger N G, Lee C, Anderson K E. Disorders of hem biosynthesis.. In: Inborn Metabolic Diseases. 4rd ed.. Heidelberg: Springer; 2006: 451-464
18 Fernandes J. The effect of disaccharides on the hyperlactacidaemia of glucose-6-phosphatase-deficient children. Acta Paediatr Scand. 1974; 63 695-698
19 Franco L M, Krishnamurthy V, Bali D et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis. 2005; 28 153-162
20 Geberhiwot T, Alger S, McKiernan P et al. Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX. J Inherit Metab Dis. 2007; 30 406
21 Greene H L, Swift L L, Knapp H R. Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease. J Pediatr. 1991; 119 398-403
22 Häussinger D. Düsseldorfer Kompendium. Düsseldorf University Press; 2009
23 Hift R J, Meissner P N. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine. 2005; 84 48-60
24 Jaeken J, Pirard M, Adamowicz M, Pronicka E, van Schaftingen E. Inhibition of phosphomannose isomerase by fructose 1-phosphate: an explanation for defective N-glycosylation in hereditary fructose intolerance. Pediatr Res. 1996; 40 764-766
25 Kemmer C, Riedel H, Köstler E, Pätzold K. Paracrystalline needle-shaped cytoplasmic liver cell inclusions in chronic hepatic porphyria – light and electron microscopic examination of liver biopsy specimens. Zentralbl Allg Pathol. 1983; 127 253-264
26 Kiechl S, Kohlendorfer U, Thaler C et al. Different clinical aspects of debrancher deficiency myopathy. J Neurol Neurosurg Psychiatry. 1999; 67 364-368
27 Kishnani P S, Chuang T P, Bali D et al. Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. Hum Mol Genet. 2009; 18 4781-4790
28 Kim S Y, Jun H S, Mead P A, Mansfield B C, Chou J Y. Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. Blood. 2008; 111 5704-5711
29 Kao K J, Coleman R A, Pizzo S V. The bleeding diathesis in human glycogen storage disease type I: in vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation. Thromb Res. 1980; 18 683-692
30 Köstler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother. 2005; 6 377-383
31 Lindberg R L, Martini R, Baumgartner M et al. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest. 1999; 103 1127-1134
32 Linet M S, Gridley G, Nyrén O et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol. 1999; 149 1010-1015
33 Lindhout M, Rubio-Gozalbo M E, Bakker J A et al. Direct non-radioactive assay of galactose-1-phosphate: uridyltransferase activity using high performance liquid chromatography. Clin Chim Acta. 2010; 411 980-983
34 Lossos A, Meiner Z, Barash V et al. Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol. 1998; 44 867-72
35 Mairovitz V, Labrune P, Fernandez H et al. Contraception and pregnancy in women affected by glycogen storage diseases. Eur J Pediatr. 2002; 161 (Suppl 1) 97-101
36 Matern D, Starzl T E, Arnaout W et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr. 1999; 158 (Suppl 2) 43-48
37 Mühlhausen C, Schneppenheim R, Budde U et al. Decreased plasma concentration of von Willebrand factor antigen (VWF:Ag) in patients with glycogen storage disease type Ia. J Inherit Metab Dis. 2005; 28 945-950
38 Müller-Wiefel D E, Steinmann B, Holm-Hadulla M et al . Infusion-associated kidney and liver failure in undiagnosed hereditary fructose intolerance. Dtsch Med Wschr. 1983; 108 985-989
39 Ockner R K, Kaikaus R M, Bass N M. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology. 1993; 18 669-676
40 Panis B, Forget P P, van Kroonenburgh M J. et al . Bone metabolism in galactosemia. Bone. 2004; 35 982-987
41 Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol. 2009; 55 72-83
42 Santer R, Steinmann B, Schaub J. Fanconi-Bickel syndrome – a congenital defect of facilitative glucose transport. Curr Mol Med. 2002; 2 213-27
43 Santer R, Rischewski J, von Weihe M et al . The spectrum of aldolase B (ALDOB) mutations and the prevalence of hereditary fructose intolerance in Central Europe. Hum Mutat. 2005; 25 594
44 Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006; 135 281-292
45 Smit G PA, Rake J P, Akman H O, DiMauro S. Glycogen storage diseases and related disorders.. In: Inborn Metabolic Diseases. 4rd ed.. Heidelberg: Springer; 2006: 101-119
46 Steinmann B, Santer R, van den Berghe G. Disorders of fructose metabolism.. In: Inborn Metabolic Diseases. 4rd ed.. Heidelberg: Springer; 2006: 135-142
47 Stölzel U, Köstler E, Koszka C et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology. 1995; 21 1500-1503
48 Talente G M, Coleman R A, Alter C. et al . Glycogen storage disease in adults. Ann Intern Med. 1994; 120 218-226
49 Van den Berghe G. Metabolic effects of fructose in the liver. Curr Top Cell Regul. 1978; 13 97-135
50 Waggoner D D, Buist N R, Donnell G N. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis. 1990; 13 802-818
51 Weinstein D A, Correia C E, Saunders A C, Wolfsdorf J I. Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. Mol Genet Metab. 2006; 87 284-288
52 Wiesmann U N, Rosé-Beutler B, Schlüchter R. Leguminosae in the diet: the raffinose-stachyose question. Eur J Pediatr. 1995; 154 (Suppl 2) 93-96
53 Wolfsdorf J I, Weinstein D A. Glycogen storage diseases. Rev Endocr Metab Disord. 2003; 4 95-102
54 Yiu W H, Mead P A, Jun H S, Mansfield B C, Chou J Y. Oxidative stress mediates nephropathy in type Ia glycogen storage disease. Lab Invest. 2010; 90 620-629

Prof. Dr. Dieter Häussinger

Klinik für Gastroenterologie, Hepatologie und Infektiologie
Heinrich-Heine-Universität Düsseldorf

Moorenstraße 5

40225 Düsseldorf

Phone: 0211/8116330

Fax: 0211/8118752

Email: haeussin@uni-duesseldorf.de